Thermal enhancement effect on chemo-radiation of Glioblastoma multiform

Background: Hyperthermia plays a significant role in the chemo-radiotherapy effect in different malignancies. In this research, we treated Glioblastoma multform (GBM) patents with hyperthermia (HT) along with the chemoradiaton, in order to evaluate HT efficacy in terms of tumor volume changes, survival tme, and probability. Materials and Methods: Thirty-eight GBM patents were distributed into two groups identfied as chemoradiaton (CRT), and also CRT plus HT (CRHT). The Karnofsky Performance Status Scale (KPS) was done before, immediately and three months after treatments. Capacitve hyperthermia device was used at frequency of 13.56 MHz (Celsius 42+ GmbH, Germany) for HT one hour before the radiotherapy for 10-12 sessions. Patents in both groups underwent MR imaging (1.5 Tesla) before, 3 and 6 months after the treatments. Thermal enhancement factors (TEF) were atained in terms of clinical target volume changes, TEF(CTV), and survival probability (SP) or TEF(SP). Results: Age ranges were from 27-73 years (Mean=50) and 27-65 years (Mean=50) for CRT and CRHT groups, respectvely. For 53 and 47 of cases biopsy and partal resecton were accomplished in both groups, respectvely. Means and standard deviatons of tumor volumes were 135.42±92.5 and 58.4±104.1cm3before treatment in CRT and CRHT groups, respectvely, with no significant difference (P= 0.2). TEF(CTV) value was atained to be as 1.54 and 1.70 for three and six months after treatments, respectvely, TEF(SP) was also equal to the 1.90. Conclusion: HT enhanced the chemoradiaton effects throughout the patent survival probability and KPS. TEF may reflect the hyperthermia efficacy for a given radiaton dose. © 2020 Novin Medical Radiation Institute. All rights reserved